The MD Anderson Manual of Medical Oncology, Fourth Edition

Expert, hands-on guidance for the practicing oncologist―from the leader in the field of cancer management―completely updated to reflect the latest advances

A Doody's Core Title for 2022! 

Comprehensive and authoritative, The MD Anderson Manual of Medical Oncology delivers everything you need to accurately diagnose and effectively treat a wide range of cancers―including leukemia, lymphoma, myeloma, lung and breast cancer, genitourinary carcinoma, melanoma, and sarcoma.

This unmatched resource emphasizes practical, actionable steps to cancer treatment, providing "to the point" recommendations, chapter summary boxes, tables, charts, expert opinion and patient education boxes, practice tips, cases, and prescriptive advice. The new format of this updated edition quickly guides you to the topic, the affiliated relevant chapter, new findings affecting clinical practice, and reference/evidence.

This fourth edition features:

• NEW Q&A, cases, patient education information, and expert advice
• Expanded coverage of immunotherapy treatment―written by the 2018 Nobel Prize-winner for immunology
• Access to continually updated online content
• A comparative table with guidelines from the European Society of Medical Oncology and the American Society of Clinical Oncology
• An emphasis on recent developments in precision medicine and immunotherapies

• Cord blood transplant
• Haploidentical cell transplantation
• Cellular therapy in allogeneic hematopoietic cell transplantation
• Pediatric cancers
• Molecular biomarkers and cancer
• Immune-oncology
• Targeted therapies in cancer
• Applied biostatistics
• Oncocardiology
• Pulmonary complications of cancer associated thrombosis

Hagop Kantarjian, MD, is Professor and Chair of the Department of Leukemia and the Samsung Distinguished Leukemia Chair in Cancer Medicine at The University of Texas MD Anderson Cancer Center. He is the author of 1,800+ peer-reviewed publications, and his research and collaborations were the basis for FDA approvals of more than 20 leukemia.

Robert A. Wolff, MD, is Professor of Medicine in the Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center Deputy Division Head. He also serves as Clinical and Educational Affairs, Division of Cancer Medicine Program Director, Hematology/Oncology Fellowship.

Alyssa G. Rieber, MD, is Department Chair, Department of General Oncology, Division of Cancer Medicine Associate Professor; Department of General Oncology, Division of Cancer Medicine; Fellowship Program Associate Director, Division of Cancer Medicine; Center Medical Director, Division of MD Anderson Oncology Program at Lyndon B Johnson Hospital, The University of Texas MD Anderson Cancer Center.

Robert Wolff, MD Professor of Medicine Department of Gastrointestinal Medical Oncology The University of Texas M. D. Anderson Cancer Center Houston, Texas

Hagop Kantarjian, MD, is Professor and Chair of the Department of Leukemia and the Samsung Distinguished Leukemia Chair in Cancer Medicine at The University of Texas MD Anderson Cancer Center. He is the author of 1,800+ peer-reviewed publications, and his research and collaborations were the basis for FDA approvals of more than 20 leukemia.

Robert A. Wolff, MD, is Professor of Medicine in the Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center Deputy Division Head. He also serves as Clinical and Educational Affairs, Division of Cancer Medicine Program Director, Hematology/Oncology Fellowship.

Alyssa G. Rieber, MD, is Department Chair, Department of General Oncology, Division of Cancer Medicine Associate Professor; Department of General Oncology, Division of Cancer Medicine; Fellowship Program Associate Director, Division of Cancer Medicine; Center Medical Director, Division of MD Anderson Oncology Program at Lyndon B Johnson Hospital, The University of Texas MD Anderson Cancer Center.